GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
=== Silica aerogel === Silica aerogels are the most common type of aerogel, and the primary type in use or study. It is silica-based and can be derived from silica gel or by a modified Stöber process. Nicknames include frozen smoke, solid smoke, solid air, solid cloud, and blue smoke, owing to its translucent nature and the way light scatters in the material. The lowest-density silica nanofoam weighs 1,000 g/m3, which is the evacuated version of the record-aerogel of 1,900 g/m3. The density of air is 1,200 g/m3 (at 20 °C and 1 atm). The silica solidifies into three-dimensional, intertwined clusters that make up only 3% of the volume. Conduction through the solid is therefore very low. The remaining 97% of the volume is composed of air in extremely small nanopores. The air has little room to move, inhibiting both convection and gas-phase conduction. Silica aerogel also has a high optical transmission of ~99% and a low refractive index of ~1.05. It is very robust with respect to high power input beam in continuous wave regime and does not show any boiling or melting phenomena. This property permits to study high intensity nonlinear waves in the presence of disorder in regimes typically unaccessible by liquid materials, making it promising material for nonlinear optics. This aerogel has remarkable thermal insulative properties, although its thermal conductivity depends on formulation, density, pressure and measurement method.
The aldehyde groups of the triose sugars are oxidised, and inorganic phosphate is added to them, forming 1,3-bisphosphoglycerate. The hydrogen is used to reduce two molecules of NAD+, a hydrogen carrier, to give NADH + H+ for each triose. Hydrogen atom and ion balance and charge balance are both maintained because the phosphate (Pi) group actually exists in the form of a hydrogen phosphate anion (HPO2−4), which dissociates to contribute the extra H+ ion and gives a net charge of −3 on both sides. Here, arsenate ([AsO4]3−), an anion akin to inorganic phosphate may replace phosphate as a substrate to form 1-arseno-3-phosphoglycerate. This, however, is unstable and readily hydrolyzes to form 3-phosphoglycerate, the intermediate in the next step of the pathway. As a consequence of bypassing this step, the molecule of ATP generated from 1–3 bisphosphoglycerate in the next reaction will not be made, even though the reaction proceeds. As a result, arsenate is an uncoupler of glycolysis.
== Death == Kimon Georgiev died suddenly of a stroke at around 1 pm on 28 September 1969 at the rest station of the Council of Ministers in Varna, shortly after visiting the Varna Thermal Power Plant, which had opened a month earlier. He was buried on 30 September in the Central Sofia Cemetery with state honours, with Prime Minister Todor Zhivkov attending the ceremony.
Sources: en.wikipedia.org
=== Secondary and tertiary structures === Chymopapain's structure was solved by X-ray diffraction techniques. Analysis of this structure showed chymopapain to have 7 alpha helix regions, 10 beta sheet regions and 2 loop turns. These 2 turns are the main difference between chymopapain's structure and other papaya proteinase proteins such as papain or caricain, which have similar conformations. Besides, chymopapain presents 3 disulfide bonds as post-traducional modifications stablished between residues 156–197, 190–229 and 287–338.
On 2 March, Hospital Moinhos de Vento, the largest of the hospitals within private networks in Rio Grande do Sul, had to rent a container in order to store the bodies of dead patients at the hospital, since the morgue in the hospital had also reached capacity. The collapse of the health system continued with daily records of hospitalizations in the city. In the Hospital de Clínicas, there were not enough specialized respirators. Along with this, health professionals had to choose which patients they should intubate, due to a lack of beds. Some patients went to be intubated at hospitals and would die there. At Hospital da Restinga, patients in the overcrowded emergency ward received care sitting in chairs due to the lack of stretchers. In some hospitals, some patients died in the hospital corridors due to a lack of beds. On 5 March, the state government also announced a fine of up to 4,000 real for those who did not wear masks, in an attempt to contain the spread of COVID-19. Melo, however, declared that the city would not apply the standard, saying he would not have people abide by the decision and that the usage of prevention methods would depend on the "conscience" of people. The municipality sought to disperse encampments at different points in the city, primarily in the Cidade Baixa neighborhood, considered a hotbed for petty crime and drug use. On the 10th and 14 March, two anti-government protests called for the reopening of local businesses and military intervention, respectively. They were held despite guidance against large gatherings.
== History == Food technologists have long known that protein hydrolysis produces a meat bouillon-like odor and taste. Hydrolysates have been a part of the human diet for centuries, notably in the form of fermented soy sauce, or Shoyu. Shoyu, traditionally made from wheat and soy protein, has been produced in Japan for over 1,500 years, following its introduction from mainland China. The origins of producing these materials through the acid hydrolysis of protein (aHVP) can be traced back to the scarcity and economic challenges of obtaining meat extracts during the Napoleonic wars. In 1831, Berzelius obtained products having a meat bouillon taste when hydrolysing proteins with hydrochloric acid. Julius Maggi produced acid-catalyzed hydrolyzed vegetable protein industrially for the first time in 1886. In 1906, Fischer found that amino acids contributed to the specific taste. In 1954, D. Phillips found that the bouillon odor required the presence of proteins containing threonine. Another important substance that gives a characteristic taste is glutamic acid.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.